Next Article in Journal
Blockchains for Secure Digitized Medicine
Previous Article in Journal
Access to Genetic Counselors in the Southern United States
 
 
Search for Articles:
Title / Keyword
Author / Affiliation
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JPM
Volume 9
Issue 3
10.3390/jpm9030034
jpm-logo
Submit to this Journal Review for this Journal Edit a Special Issue
► Article Menu

Article Menu

share announcement question_answer thumb_up
...
textsms
...
Case Report

Adaptive, Iterative, Long-Term Personalized Therapy Management in a Case of Stage IV Refractory NSCLC

by
Anantbhushan Ranade
1,
Darshana Patil
2,
Amit Bhatt
1,
Rucha Dhasare
1,
Vineet Datta
2,
Rajan Datar
2 and
Dadasaheb Akolkar
2,*
1
Avinash Cancer Clinic, Tilak Road, Pantancha Gate, Sadashiv Peth, Pune 411030, Maharashtra, India
2
Datar Cancer Genetics Ltd., F-8 D-Road, Ambad, Nasik 422010, Maharashtra, India
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2019, 9(3), 34; https://doi.org/10.3390/jpm9030034
Received: 19 June 2019 / Accepted: 3 July 2019 / Published: 5 July 2019
View Full-Text Download PDF
Browse Figures

Abstract

In this paper we report long-term therapy management based on iterative de novo molecular and cellular analysis in a case of metastatic non-small cell lung cancer (NSCLC), with prior history of treated colorectal cancer. In the described case temporal tumor evolution, emergent therapy resistance and disease recurrences were addressed via the administration of personalized label- and organ-agnostic treatments based on de novo tumor profiling. This adaptive and iterative treatment strategy countered disease progression at each instance and led to the durable regression of primary as well as metastatic lesions. Concurrently, serial evaluation of mutations in cell-free circulating tumor DNA (ctDNA) via liquid biopsy (LBx) was performed to monitor disease status, ascertain treatment response, identify emergent drug resistance and detect recurrence at sub-radiological levels. The treatment management strategy described herein effectively addressed multiple, sequential clinical conundrums for which viable options were unavailable under the current Standard of Care (SoC). View Full-Text
Keywords: non small cell lung cancer (NSCLC); precision oncology; personalized therapy management non small cell lung cancer (NSCLC); precision oncology; personalized therapy management
►▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

SciFeed

Share and Cite

MDPI and ACS Style

Ranade, A.; Patil, D.; Bhatt, A.; Dhasare, R.; Datta, V.; Datar, R.; Akolkar, D. Adaptive, Iterative, Long-Term Personalized Therapy Management in a Case of Stage IV Refractory NSCLC. J. Pers. Med. 2019, 9, 34. https://doi.org/10.3390/jpm9030034

AMA Style

Ranade A, Patil D, Bhatt A, Dhasare R, Datta V, Datar R, Akolkar D. Adaptive, Iterative, Long-Term Personalized Therapy Management in a Case of Stage IV Refractory NSCLC. Journal of Personalized Medicine. 2019; 9(3):34. https://doi.org/10.3390/jpm9030034

Chicago/Turabian Style

Ranade, Anantbhushan, Darshana Patil, Amit Bhatt, Rucha Dhasare, Vineet Datta, Rajan Datar, and Dadasaheb Akolkar. 2019. "Adaptive, Iterative, Long-Term Personalized Therapy Management in a Case of Stage IV Refractory NSCLC" Journal of Personalized Medicine 9, no. 3: 34. https://doi.org/10.3390/jpm9030034

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Map by Country/Region

1
Back to TopTop